Based on the key indicators related to Lyra Therapeutics' liquidity, profitability, solvency, and operating efficiency, Lyra Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At present, Lyra Therapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Liabilities is expected to grow to about 17 M, whereas Other Current Liabilities is forecasted to decline to about 5 M. Key indicators impacting Lyra Therapeutics' financial strength include:
The financial analysis of Lyra Therapeutics is a critical element in measuring its lifeblood. Investors should not minimize Lyra Therapeutics' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Please note, the presentation of Lyra Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Lyra Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Lyra Therapeutics' management manipulating its earnings.
Lyra Therapeutics Stock Summary
Lyra Therapeutics competes with CytomX Therapeutics, Assembly Biosciences, Achilles Therapeutics, Instil Bio, and NextCure. Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts. Lyra Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 60 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Lyra Therapeutics's current stock value. Our valuation model uses many indicators to compare Lyra Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lyra Therapeutics competition to find correlations between indicators driving Lyra Therapeutics's intrinsic value. More Info.
Lyra Therapeutics is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At present, Lyra Therapeutics' Return On Equity is projected to drop slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Lyra Therapeutics' earnings, one of the primary drivers of an investment's value.
Lyra Therapeutics Systematic Risk
Lyra Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Lyra Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Lyra Therapeutics correlated with the market. If Beta is less than 0 Lyra Therapeutics generally moves in the opposite direction as compared to the market. If Lyra Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Lyra Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Lyra Therapeutics is generally in the same direction as the market. If Beta > 1 Lyra Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Lyra Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Lyra Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Lyra Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio
(0.0112)
At present, Lyra Therapeutics' Price Earnings To Growth Ratio is projected to increase slightly based on the last few years of reporting.
Lyra Therapeutics March 22, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Lyra Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Lyra Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Lyra Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Lyra Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Lyra Therapeutics's daily price indicators and compare them against related drivers.
When running Lyra Therapeutics' price analysis, check to measure Lyra Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lyra Therapeutics is operating at the current time. Most of Lyra Therapeutics' value examination focuses on studying past and present price action to predict the probability of Lyra Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lyra Therapeutics' price. Additionally, you may evaluate how the addition of Lyra Therapeutics to your portfolios can decrease your overall portfolio volatility.